To access the formulary status of ZETIA using this tool, simply select your state from the first drop-down menu, then specify your managed care market by selecting from the second drop-down menu.
Formulary status is believed to be accurate but cannot be guaranteed. Formulary status for national plans may not reflect plan variation at the local level.
Updated formulary status information for Medicare plans may be available from the Centers for Medicare & Medicaid Services: www.medicare.gov.
| The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. | |
| ZETIA, administered alone or in combination with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated TOTAL-C, LDL-C, and Apo B in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia when diet alone is not enough. | |
| Contraindications: hypersensitivity to any component of this medication. | |
| Statin contraindications apply when used with a statin: active liver disease; unexplained persistent elevations in hepatic transaminase levels. Statins are contraindicated in pregnant and nursing women. Refer to the statin label for details. | |
| SELECTED CAUTIONARY INFORMATION | |
| When using ZETIA with a statin, also follow the label recommendations for that specific statin. | |
| When ZETIA was coadministered with a statin, consecutive elevations in hepatic transaminase levels (≥3 × ULN) were slightly higher (1.3%) than those of statins alone (0.4%). Liver function tests should be performed when ZETIA is added to statin therapy and according to statin recommendations. Should an increase in ALT or AST ≥3 × ULN persist, consider withdrawal of ZETIA and/or the statin. | |
| Patients should be advised to promptly report muscle pain, tenderness, or weakness. Risk for skeletal muscle toxicity increases with higher statin doses, advanced age (>65), hypothyroidism, renal impairment, and depending on the statin used, concomitant use of other drugs. Discontinue drug if myopathy is diagnosed or suspected. |
|
Before prescribing ZETIA, please read the Prescribing Information.
This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.
For non-US health care professionals, click here.
ZETIA and VYTORIN are registered trademarks of MSP Singapore Company, LLC.
MerckMedicus™, MerckSource®, and MerckServices® are trademarks of Merck & Co., Inc.
Copyright © 2010 Merck/Schering-Plough Pharmaceuticals, a subsidiary of Merck & Co., Inc. All rights reserved.
21050228(1)-06/10-ZET

